Table 1.

Antitumor Effects of Oral ST1481 Delivered by Two Different Treatment Schedules Against the A549 Human Lung Carcinoma Xenograft

Note: Treatments from day 18 (mean TV ≅ 250 mm3).

DrugScheduleDose (mg/kg)TVI%abLCKcAIadMVI%ae
10% DMSO2.6 ± 1.1
ST1481q4dx42670.75.5 ± 1.2***45***
ST1481qdx5/wx2w0.583*≫1.25.6 ± 0.7***61*****
  • a Thirty-six days after the tumor inoculum, i.e., 7 days after treatment ended.

  • b TVI% = TV inhibition percentage in treated versus control mice.

  • c LCK = log10 cell kill (to 600 mm3 of tumor).

  • d AI = Apoptotic Index = number of apoptotic nuclei/total number of cells × 100. Means ± SD are reported.

  • e MVI% = microvessel (CD31+ cells) inhibition percentage = 100− (mean MV density in treated/mean MV density in control tumors × 100).

  • *** P < 0.0001 versus control mice, by Student's t test.

  • * P < 0.01 versus q4dx4 drug-treated mice.

  • ** P < 0.0005 versus q4dx4 drug-treated mice.